From: SAVER: sodium valproate for the epigenetic reprogramming of high-risk oral epithelial dysplasia—a phase II randomised control trial study protocol
Change in lesion size
Code
≥ 75% decrease
3
50–74 % decrease
2
25–49% decrease
1
0–24% decrease or increase
0
25–49% increase
− 1
50–74% increase
− 2
≥ 75% increase
− 3